Clinical Trials Browser

Interventional × nazartinib × Clear all

NCT03333343 2026-01-16

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Phase 1 Active not recruiting

EGFR-mutant Non-small Cell Lung Cancer

NCT03114319 2025-08-28

Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors

Phase 1 Terminated

DermatologicGastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Melanoma, Noonan Syndrome

NCT03292133 2025-06-10

A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer

Phase 2 Terminated

11 enrolled 10 charts

Lung Neoplasms

NCT02108964 2024-12-11

A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies

Phase 1/2 Completed

225 enrolled 31 charts

Advanced Non-small Cell Lung Cancer

NCT03516214 2024-02-15

EATON

Phase 1 Completed

Bronchial Neoplasms

NCT02335944 2023-06-18

Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.

Phase 1/2 Terminated

177 enrolled 48 charts

Carcinoma, Non-Small-Cell Lung

NCT02900664 2022-03-29

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Phase 1 Completed

BreastGastrointestinalThoracic

Adenocarcinoma of Lung, Adenocarcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Intestinal Neoplasms, Lung Neoplasms, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Ductal, Triple Negative Breast Neoplasms

NCT02323126 2022-02-28

Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer

Phase 2 Terminated

64 enrolled 28 charts

Carcinoma, Non-Small-Cell Lung

NCT03529084 2019-11-22

Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations

Phase 3 Withdrawn

Carcinoma, Non-Small-Cell Lung